Scapa (SCPA) chief executive Heejae Chae has reversed his decision to stand down from his role, as the adhesive products specialist pursues legal action against ConvaTec (CTEC) after it exited a “material” supply deal with its healthcare arm. ConvaTec cancelled its agreement last month in response to Scapa’s acquisition of Systagenix Wound Management, a ConvaTec competitor, a move that the medical technology group deemed in breach of its deal, which Scapa denies. Scapa has taken measures to reduce the estimated impact on revenues and trading profit in FY20. After a reduction in direct labour, while assuming no further mitigating actions at present, its estimated exposure to revenue and trading profit in FY20 could be around £28m and £13m respectively. This includes the impact on other facilities which provide materials for ConvaTec products in Knoxville. Scapa shares rose 16 per cent in morning trading.
RNS Number: 8030 A ConvaTec Group PLC 31 May 2019 ConvaTec Group Plc- Total Voting Rights. The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6. 1. The above figure can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify...
RNS Number: 4360 Z ConvaTec Group PLC 17 May 2019 17 May 2019. The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility in ordinary shares of 10 pence each in the share capital of the Company.. On 16 May 2019 Mr Rick Anderson, Executive Chairman and Chief Executive Officer, acquired 1,680 Shares at £1.3728 per...
RNS Number: 5704 Y ConvaTec Group PLC 09 May 2019. Results of Annual General Meeting. Reading, United Kingdom 9 May 2019- Poll Result.
RNS Number: 9631 X ConvaTec Group PLC 03 May 2019. ·Group revenue of $430.6 million included an additional one-off provision in the quarter of $8.9 million, arising from a change of accounting methodology as detailed below. o Advanced Wound Care: ongoing drag from legacy portfolio and continuing trends from Q4' 18- underperformance in the US and negative channel...
RNS Number: 4362 X ConvaTec Group PLC 29 April 2019 ConvaTec Group Plc. On 12 February 2019, the Board of Directors of ConvaTec Group Plc proposed a final dividend in respect of 2018, subject to shareholder approval at the Annual General Meeting on 9 May 2019 of 3.983 cents per share. It is confirmed that 11,198,285 ordinary shares of 10 pence each will be allotted...
RNS Number: 6755 W ConvaTec Group PLC 18 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
On 12 February 2019, the Board of Directors of ConvaTec Group Plc proposed a final dividend of 3.983 cents per share subject to shareholder approval at the Annual General Meeting on 9 May 2019. The dividend is payable in cash in sterling to holders of ordinary shares, the chosen exchange rate for this payment is $1.286/ £1.00, giving a total sterling dividend of...
RNS Number: 8981 V ConvaTec Group PLC 11 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7620 V ConvaTec Group PLC 10 April 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9703 U ConvaTec Group PLC 03 April 2019. READING, UNITED KINGDOM- ConvaTec Group Plc, a global medical products and technologies company, has today published on the Group's website its Notice of Annual General Meeting. The Annual General Meeting will be held at 11 am on Thursday 9 May 2019 at The Concert Hall, Reading Town Hall, Blagrave Street, Reading RG1...
RNS Number: 5098 U ConvaTec Group PLC 29 March 2019 29 March 2019. The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility in ordinary shares of 10 pence each in the share capital of the Company.. On 28 March 2019, the Company's Chief Financial Officer and a PDMR, sold and bought 165,000 Shares at a price of...
RNS Number: 5048 U ConvaTec Group PLC 29 March 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0698 U ConvaTec Group PLC 26 March 2019 26 March 2019. The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility in ordinary shares of 10 pence each in the share capital of the Company.. On 25 March 2019, the Company's Interim Chief Executive Officer and a PDMR, purchased 55,500 Shares at £1.3685 per...
Medical devices maker ConvaTec Group has announced that Karim Bitar, chief executive of animal genetics company Genus, will join as its new chief executive from September 30. ConvaTec chairman Sir Christopher Gent has advised that he wishes to retire and will not seek re-election as a director at the annual general meeting in May.
ConvaTec Group Plc (CTEC.L) Announced the appointment of Karim Bitar as Chief Executive Officer, effective from 30 September 2019. Following this appointment, Sir Christopher Gent, the Chairman, has advised the Board that he wishes to retire and therefore will not seek re-election as a Director at the Group's forthcoming Annual General Meeting on 9 May 2019. A Special Nominations Committee has been established to identify Sir Christopher's successor as Chair of the Board. Rick Anderson, currently interim Chief Executive Officer ("CEO") of ConvaTec, has agreed to temporarily serve as Executive Chairman until a new Chair has been appointed, effective from 9 May 2019. The Board also announced that Steve Holliday, Deputy Chairman and Senior Independent Director, has resigned as a member of the Board with effect from 31 March 2019. In his place, Margaret Ewing will be appointed as Senior Independent Director from that date and Ros Rivaz will be appointed as Chair of the Remuneration Committee and member of the Audit & Risk Committee.
RNS Number: 8064 T ConvaTec Group PLC 25 March 2019 This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation 596/ 2014. Reading, United Kingdom- Today, the Board of ConvaTec Group Plc announced the appointment of Karim Bitar as Chief Executive Officer, effective from 30 September 2019. Following this appointment,...
RNS Number: 8063 T ConvaTec Group PLC 25 March 2019 This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation 596/ 2014. Reading, United Kingdom- The Board of ConvaTec Group Plc is very pleased to announce the appointment of Karim Bitar as Chief Executive Officer with an effective date of 30 September, 2019..
RNS Number: 0602 S ConvaTec Group PLC 06 March 2019 6 March 2019. The Company announces the following change in the interests of a Director in ordinary shares of 10 pence each in the share capital of the Company.. The closing share price on 5 March 2019 of �1.376 was used in determining the number of shares to be granted under the deferred bonus provisions..
RNS Number: 3078 R ConvaTec Group PLC 27 February 2019. READING, UNITED KINGDOM- ConvaTec Group Plc, a leading global medical products and technologies company, has today published on the Group's website its Annual Report& Accounts for the year ended 31 December 2018. The Annual Report is available at www.convatecgroup.com..
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    1.97B

Company Profile

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Its products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Based in Reading, it employs over 9,000 people in more than 100 countries.

Classification

Market Indices-

Locations

HQ
3 Forbury Place
23 Forbury Road
Reading
RG1 3JH
Watchlist